Acuity and colour vision changes post intravitreal dexamethasone implant injection in patients with diabetic macular oedema

被引:8
|
作者
Abdel-Hay, Ahmed [1 ,2 ]
Sivaprasad, Sobha [3 ]
Subramanian, Ahalya [1 ]
Barbur, John L. [1 ]
机构
[1] City Univ London, Appl Vis Res Ctr, London, England
[2] Musgrove Pk Hosp, Taunton, Somerset, England
[3] Moorfields Eye Hosp, London, England
来源
PLOS ONE | 2018年 / 13卷 / 06期
关键词
CHROMATIC SENSITIVITY; NEURAL APOPTOSIS; CLASSIFICATION; TRIAMCINOLONE; RETINOPATHY; PREVALENCE; PATHWAYS; HYPOXIA; SYSTEM;
D O I
10.1371/journal.pone.0199693
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Purpose To evaluate changes in colour vision following intravitreal injection of Dexamethasone implant (Ozurdex) in patients with diabetic macular oedema (DMO). Both red-green (RG) and yellow-blue (YB) chromatic sensitivity were assessed using the Colour Assessment & Diagnosis (CAD) test which isolates the use of colour signals and provides age-corrected, statistical limits for normal trichromats. To determine whether colour changes and visual acuity (VA) post-treatment relate to central sub-field retinal thickness (CST). Methods Fourteen patients with DMO who were undergoing treatment with Ozurdex were recruited for this study. RG and YB colour thresholds were measured using the CAD test, best corrected visual acuity was assessed using the ETDRS chart and CST was measured using spectral domain optical coherence tomography (SD-OCT). All tests were performed monocularly at baseline and 24 weeks post injection. Results All patients (n = 14 eyes), had significant loss of RG and YB chromatic sensitivity at baseline (p<0.05). The mean age was 56 +/- 9.5 years. The age specific, monocular, upper normal limits for a 56 year old subject are 2.66 for RG and 2.85 for YB. In this study, the measured, pre injection thresholds (mean +/- SD) were 22.6 +/- 11.3 for RG and 16.2 +/- 3.76 for YB. There was significant improvement in RG threshold post injection (i.e., 19.2 +/- 10.8 (p<0.05)). No significant changes were found in the YB thresholds with corresponding mean and range values of: 15.8 +/- 4.6 (p = 0.23). CST pre-treatment was 542 +/- 135 mu m. After treatment and by week 24 the CST values decreased to 435 +/- 127 mu m. Conclusions RG colour thresholds provide a sensitive measure of functional change in diabetic subjects with macular oedema. The YB system is damaged severely in the DMO patients studied and shows little or no recovery post treatment. The improvement in VA and particularly in RG colour vision correlate well with the measured decrease in CST. The results suggest that the improvement in the RG chromatic sensitivity can provide a useful biomarker for monitoring the efficacy of treatment in DMO.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Morphological and functional changes in recalcitrant diabetic macular oedema after intravitreal dexamethasone implant
    Iacono, Pierluigi
    Parodi, Maurizio Battaglia
    Scaramuzzi, Matteo
    Bandello, Francesco
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2017, 101 (06) : 791 - 795
  • [2] INTRAVITREAL DEXAMETHASONE IMPLANT IN EYES WITH CHRONIC REFRACTORY DIABETIC MACULAR OEDEMA
    Giralt, Juan
    Alforja, Socorro
    Keller, Johannes
    Latasiewicz, Marta
    Fontecilla, Christian
    Adan Civera, Alfredo
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [3] Aqueous Humour Cytokine Changes with Intravitreal Dexamethasone Implant Injection for Diabetic Macular Edema
    Figueras-Roca, Marc
    Sala-Puigdollers, Anna
    Alforja, Socorro
    Torras, Josep
    Peraza-Nieves, Jorge
    Zarranz-Ventura, Javier
    Adan Civera, Alfredo
    Molins, Blanca
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2019, 27 (08) : 1203 - 1210
  • [4] Perspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema
    Mehta, Hemal
    Gillies, Mark
    Fraser-Bell, Samantha
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2015, 6 (05) : 234 - 245
  • [5] Budget impact analysis of dexamethasone intravitreal implant for the treatment of diabetic macular oedema
    Cervera, Enrique
    de Andres-Nogales, Fernando
    Armada, Felix
    Arias, Luis
    Oyaguez, Itziar
    Martinez, Concha
    FARMACIA HOSPITALARIA, 2018, 42 (06) : 244 - 250
  • [6] EFFECT OF DEXAMETHASONE INTRAVITREAL IMPLANT, OZURDEX®, ON DIABETIC MACULAR OEDEMA DURING PREGNANCY
    Ba-Ali, S.
    Valerius, M.
    Hodzic-Hadzibegovic, D.
    Tornes, M. H.
    Lund-Andersen, H.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2016, 26 (04) : E110 - E110
  • [7] Retinal vascular calibre changes after intravitreal bevacizumab or dexamethasone implant treatment for diabetic macular oedema
    Wickremasinghe, Sanjeewa S.
    Fraser-Bell, Samantha
    Alessandrello, Elizabeth
    Mehta, Hemal
    Gillies, Mark C.
    Lim, Lyndell L.
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2017, 101 (10) : 1329 - 1333
  • [8] The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular oedema
    Maria Vittoria Cicinelli
    Amir Rosenblatt
    Domenico Grosso
    Piero Zollet
    Luigi Capone
    Alessandro Rabiolo
    Rosangela Lattanzio
    Anat Loewenstein
    Francesco Bandello
    Eye, 2021, 35 : 3232 - 3242
  • [9] Persistent vitreous hemorrhage after intravitreal injection of dexamethasone intravitreal implant in patients with diabetic macular edema
    Li, Meng-Syuan
    Sheu, Shwu-Jiuan
    TAIWAN JOURNAL OF OPHTHALMOLOGY, 2019, 9 (04) : 280 - 283
  • [10] BUDGET IMPACT ANALYSIS OF DEXAMETHASONE INTRAVITREAL IMPLANT FOR TREATMENT OF DIABETIC MACULAR OEDEMA IN SPAIN
    de Andres-Nogales, F.
    Oyaguez, I
    Echave, M.
    Arias, L.
    Cervera, E.
    Armada, F.
    Martinez, C.
    VALUE IN HEALTH, 2016, 19 (07) : A565 - A565